CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Launches New Research Programs

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning said it is engaging in a new topical skin cream research and development (“R&D”) program; R&D regarding nicotine edibles; and provided an update on existing R&D programs. The company has developed topical cream products for the delivery of cannabinoids as an addition to its DehydraTECH™ technology. Laboratory testing for human skin absorption and penetration characteristics are scheduled for early 2018 for various formulations. Following its recent nicotine patent grant, Lexaria is advancing its research focus on edible forms of nicotine that could utilize the company’s DehydraTECH™ technology. Additionally, Lexaria plans to further expand its product line in 2018 through working on new and improved formulations for a variety of food products.

To view the full press release, visit http://cnw.fm/Np86g

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaEnergy.com.

More from CannabisNewsBreaks

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Leave a Reply